- September 9, 2025CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review…
- September 8, 2025CD73: a novel checkpoint protein STUTTGART, Germany I September 08, 2025 I La Merie Publishing announced the release of its…
- September 5, 2025IGF-1R: a validated thyroid eye disease target and a re-emerging cancer target – a pipeline review STUTTGART, Germany I September…
- September 4, 2025NaPi2b: a viable solid tumor target for novel ADC technologies – a pipeline review STUTTGART, Germany I September 04, 2025…
- September 3, 2025FcRn: a commercially and clinically validated target in a variety of antibody-mediated autoimmune diseases – a pipeline review STUTTGART, Germany…
- September 1, 2025New service: competitor analysis of targeted immunotherapies with targets selected by clients STUTTGART, Germany I September 01, 2025 I La…
- August 31, 2025KLK2: promising drug target in prostate cancer – a pipeline review STUTTGART, Germany I August 31, 2025 I La Merie…
- August 30, 2025Vectorized antibodies by in vivo expression of DNA or RNA overcome limitations of systemically administered antibodies STUTTGART, Germany I August…
- August 30, 2025STEAP1 and STEAP2: emerging prostate cancer targets – a pipeline review STUTTGART, Germany I August 30, 2025 I La Merie…
- August 27, 2025Tissue Factor: a validated target for improved solid tumor antibody-drug conjugates – a pipeline review STUTTGART, Germany I August 27,…
